Home page > Quality health systems and services | Medicines, health technology and health information | Health friendly research and innovation

intellectual property


Please find all related articles below.



Health technology assessments and innovation in health


European Ministers of Health also adopted conclusions on innovation for the benefit of patients at a Council meeting on 1 December 2014. Ministers are calling on national governments and the European Commission to cooperate more closely on the ’life cycle approach’ for new innovative medicines and move ahead with the implementation of health technology assessment. The Council conclusions highlight the importance of early dialogue between technology developers, regulatory, (...)
18/12/2014

[Report] Patients suffering from medicines shortages in all European countries


A new report on medicines shortages experienced in European healthcare systems reveals that over 86% of hospital pharmacists are experiencing difficulties in sourcing medicines with 66% reporting this as a daily or weekly problem. The top affected areas are medicines to fight infection, cancer drugs and anesthetics. Brussels, 17 November 2014 - The report by the European Association of Hospital Pharmacists (EAHP), surveyed the experiences of over 600 hospital pharmacists in 36 European (...)
17/11/2014

Carlos Moedas » European Commissioner for Research, Science and Innovation


Carlos Moedas (age 44) studied engineering at Lisbon University, Portugal and an MBA at Harvard University, USA. He worked for Goldman Sachs and EuroHypo investment bank before returning to Portugal in 2004 to join a property consulting company, and established his own property investment company in 2008. He led negotiations for the Social Democratic Party (PSD) for Portugal’s 2011 State Budget. He was elected as an MP in the same year, and leading implementation of the (...)
05/11/2014

[TTIP & Transparency Consultation] EPHA answers to the European Ombudsman Mrs Emily O’Reilly


Brussels, 30 October 2014 - On 29 July 2014, the European Ombudsman opened an own-initiative inquiry towards the European Commission concerning transparency and public participation in relation to the TTIP negotiations (OI/10/2014/RA). The present public consultation concerns that inquiry. The outcome of the TTIP negotiations could have a significant impact on the lives of citizens. The aim of the Ombudsman’s inquiry is to help ensure that the public can follow the progress of these (...)
30/10/2014

[Joint press release] The European Health Community welcomes President-elect Juncker’s decision to ensure the security of all Europeans by regulating health for the public good


October 22th 2014, Brussels – The NGO signatories of this statement wholeheartedly welcome the announcement of the reversal of the decision by President-elect Jean-Claude Juncker to move the competence for pharmaceutical and medical devices to the enterprise directorate (1). Following negotiations within the European Parliament and concerns expressed by a number of member states, President-elect Juncker stated today that the "responsibility for medicines and pharmaceutical products (...)
22/10/2014

Can we afford our medicines? The access to medicines crunch in Europe November 12 (12:30 pm - 3:00 pm), Brussels


Health is a fundamental universal right and access to medicines is part of it. The EU and its Member States are committed to universal and equitable access to healthcare. Nevertheless, millions of European patients suffer from the lack of affordability of many life-saving medicines across Europe. Download the event’s invitation * See the event’s poster An event under the auspices of MEPs Nessa CHILDERS (S&D, IE), Beatriz BECERRA BASTERRECHEA (ALDE, ES), Kostas (...)
21/10/2014

EPHA statement on the return of pharmaceutical and medical devices to the health department of the EU


October 10th 2014, Brussels – According to statements by both the S&D (1) and Green Groups (2) yesterday, it seems likely that President-elect Jean-Claude Juncker is intending to soften his decision to move pharmaceutical policy from the health portfolio to enterprise. EPHA welcomes this news as a step in the right direction and a possible cause for celebration for the European Parliament (3) and the public health community (4). “I would like to applaud President-elect (...)
10/10/2014

[Letter] To MEPs on #Pharma4Health campaign


October 8 2014, Brussels - On 10th of September, the European Commission President-elected Jean-Claude Juncker unveiled the transfer of the competence for medicinal products and health technologies from the health portfolio to the enterprise one (now called Internal Market, Industry, Entrepreneurship and SMEs). Dear Member of European Parliament, The shift of EU pharmaceutical policy will put Europe’s security at risk and is in contradiction with how pharmaceutical policy is (...)
08/10/2014

Cecilia Malmström » European Commissioner for Trade


From 1 November 2014, Cecilia Malmström will take office as the new Commissioner for Trade, under the Juncker Commission. The appointment of Swedish native Ms. Malmstrom implies that the President-elect of the European Commission, Jean-Claude Juncker, would like to further promote discussion with the U.S. on the much debated Transatlantic Trade and Investment Partnership (TTIP). By Leonardo Palumbo, EPHA Policy Coordinator for EU Affairs and Arthur Matthews, Policy Assistant As (...)
28/09/2014

Frans Timmermans » European Commissioner for Better Regulation, Inter-Institutional Relations, the Rule of Law, and and Charter of Fundamental Rights


Frans Timmermans has been officially designated to be one of the six Vice-Presidents and the First Vice-President in charge of Better Regulation, Inter-Institutional Relations, the Rule of Law and the Charter of Fundamental Rights – a newly installed Directorate General. By Dorota Sienkiewicz, EPHA Health Equity and Policy Coherence Coordinator Putting in place this brand new DG reflects the EU’s new strategy to focus on areas where it can make a difference (in its own (...)
28/09/2014